|
1
|
Docea AO, Tsatsakis A, Albulescu D,
Cristea O, Zlatian O, Vinceti M, Moschos SA, Tsoukalas D, Goumenou
M, Drakoulis N, et al: A new threat from an old enemy: Re emergence
of coronavirus (Review). Int J Mol Med. 45:1631–1643.
2020.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Tsatsakis A, Petrakis D, Nikolouzakis TK,
Docea AO, Calina D, Vinceti M, Goumenou M, Kostoff RN, Mamoulakis
C, Aschner M, et al: COVID-19, an opportunity to reevaluate the
correlation between long-term effects of anthropogenic pollutants
on viral epidemic/pandemic events and prevalence. Food Chem
Toxicol. 141(111418)2020.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Conti P, Caraffa A, Gallenga CE, Ross R,
Kritas SK, Frydas I, Younes A and Ronconi G: Coronavirus-19
(SARS-CoV-2) induces acute severe lung inflammation via IL-1
causing cytokine storm in COVID-19: A promising inhibitory
strategy. J Biol Regul Homeost Agents. 34:1971–1975.
2020.PubMed/NCBI View
Article : Google Scholar
|
|
4
|
Shi H, Wang W, Yin J, Ouyang Y, Pang L,
Feng Y, Qiao L, Guo X, Shi H, Jin R, et al: The inhibition of
IL-2/IL-2R gives rise to CD8+ T cell and lymphocyte
decrease through JAK1-STAT5 in critical patients with COVID-19
pneumonia. Cell Death Dis. 11(429)2020.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Del Valle DM, Kim-Schulze S, Huang HH,
Beckmann ND, Nirenberg S, Wang B, Lavin Y, Swartz TH, Madduri D,
Stock A, et al: An inflammatory cytokine signature predicts
COVID-19 severity and survival. Nat Med. 26:1636–1643.
2020.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Han H, Ma Q, Li C, Liu R, Zhao L, Wang W,
Zhang P, Liu X, Gao G, Liu F, et al: Profiling serum cytokines in
COVID-19 patients reveals IL-6 and IL-10 are disease severity
predictors. Emerg Microbes Infect. 9:1123–1130. 2020.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Zhu FC, Guan XH, Li YH, Huang JY, Jiang T,
Hou LH, Li JX, Yang BF, Wang L, Wang WJ, et al: Immunogenicity and
safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine
in healthy adults aged 18 years or older: A randomised,
double-blind, placebo-controlled, phase 2 trial. Lancet.
396:479–488. 2020.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Yu J, Tostanoski LH, Peter L, Mercado NB,
McMahan K, Mahrokhian SH, Nkolola JP, Liu J, Li Z, Chandrashekar A,
et al: DNA vaccine protection against SARS-CoV-2 in rhesus
macaques. Science. 369:806–811. 2020.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Calina D, Docea AO, Petrakis D, Egorov AM,
Ishmukhametov AA, Gabibov AG, Shtilman MI, Kostoff R, Carvalho F,
Vinceti M, et al: Towards effective COVID-19 vaccines: Updates,
perspectives and challenges (Review). Int J Mol Med. 46:3–16.
2020.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Isaacs A and Lindenmann J: Virus
interference. I. The interferon. Proc R Soc Lond B Biol Sci.
147:258–267. 1957.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Vilcek J and Sen GC: Interferons and other
cytokines. In: Fields Virology. Fields BN, Knipe DM and Howley PM
(eds). 3rd edition. Lippincott-Raven Publishers, Philadelphia, PA,
pp375-399, 1996.
|
|
12
|
Deonarain R, Alcami A, Alexiou M, Dallman
MJ, Gewert DR and Porter AC: Impaired antiviral response and
alpha/β interferon induction in mice lacking beta interferon. J
Virol. 74:3404–3409. 2000.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Sato M, Suemori H, Hata N, Asagiri M,
Ogasawara K, Nakao K, Nakaya T, Katsuki M, Noguchi S, Tanaka N, et
al: Distinct and essential roles of transcription factors IRF-3 and
IRF-7 in response to viruses for IFN-alpha/beta gene induction.
Immunity. 13:539–548. 2000.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Collins SE, Noyce RS and Mossman KL:
Innate cellular response to virus particle entry requires IRF3 but
not virus replication. J Virol. 78:1706–1717. 2004.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Taniguchi T, Ogasawara K, Takaoka A and
Tanaka N: IRF family of transcription factors as regulators of host
defense. Annu Rev Immunol. 19:623–655. 2001.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Garoufalis E, Kwan I, Lin R, Mustafa A,
Pepin N, ARoulston A, Lacoste J and Hiscott J: Viral induction of
the human beta interferon promoter: modulation of transcription by
NF-kappaB/rel proteins and interferon regulatory factors. J Virol.
68:4707–4715. 1994.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Paun A and Pitha PM: The IRF family,
revisited. Biochimie. 89:744–753. 2007.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Génin P, Vaccaro A and Civas A: The role
of differential expression of human interferon - a genes in
antiviral immunity. Cytokine Growth Factor Rev. 20:283–295.
2009.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Ye J and Maniatis T: Negative regulation
of interferon-beta gene expression during acute and persistent
virus infections. PLoS One. 6(e20681)2011.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Weaver BK, Kumar KP and Reich NC:
Interferon regulatory factor 3 and CREB-binding protein/p300 are
subunits of double-stranded RNA-activated transcription factor
DRAF1. Mol Cell Biol. 18:1359–1368. 1998.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Takeuchi O and Akira S: MDA5/RIG-I and
virus recognition. Curr Opin Immunol. 20:17–22. 2008.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Kato H, Sato S, Yoneyama M, Yamamoto M,
Uematsu S, Matsui K, Tsujimura T, Takeda K, Fujita T, Takeuchi O,
et al: Cell type-specific involvement of RIG-I in antiviral
response. Immunity. 23:19–28. 2005.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Kato H, Takeuchi O, Sato S, Yoneyama M,
Yamamoto M, Matsui K, Uematsu S, Jung A, Kawai T, Ishii KJ, et al:
Differential roles of MDA5 and RIG-I helicases in the recognition
of RNA viruses. Nature. 441:101–105. 2006.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Ye Y, Hauns K, Langland JO, Jacobs BL and
Hogue BG: Mouse hepatitis coronavirus A59 nucleocapsid protein is a
type I interferon antagonist. J Virol. 81:2554–2563.
2007.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Huang Z and Tunnacliffe A: Response of
human cells to desiccation: comparison with hyperosmotic stress
response. J Physiol. 558:181–191. 2004.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Strayer DR, Dickey R and Carter WA:
Sensitivity of SARS/MERS CoV to interferons and other drugs based
on achievable serum concentrations in humans. Infect Disord Drug
Targets. 14:37–43. 2014.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Tsatsakis A, Calina D, Falzone L, Petrakis
D, Mitrut R, Siokas V, Pennisi M, Lanza G, Libra M, Doukas SG, et
al: SARS-CoV-2 pathophysiology and its clinical implications: An
integrative overview of the pharmacotherapeutic management of
COVID-19. Food Chem Toxicol. 146(111769)2020.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Nakamura M, Funami K, Komori A, Yokoyama
T, Aiba Y, Araki A, Takii Y, Ito M, Matsuyama M, Koyabu M, et al:
Increased expression of Toll-like receptor 3 in intrahepatic
biliary epithelial cells at sites of ductular reaction in diseased
livers. Hepatol Int. 2:222–230. 2008.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Liu LM, Tu WJ, Zhu T, Wang XT, Tan ZL,
Zhong H, Gao DY and Liang DY: IRF3 is an important molecule in the
UII/UT system and mediates immune inflammatory injury in acute
liver failure. Oncotarget. 7:49027–49041. 2016.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Xu RH, Schuster DM, Lee JE, Smith M,
Potter J, Dhariwal G, Rosenthal K, Nathan M, Gerard GF and
Rashtchian A: One-step analysis and quantification of RNA by
RT-PCR: Using high-temperature reverse transcription. Focus.
22:3–5. 2000.
|
|
31
|
Génin P, Morin P and Civas A: Impairment
of interferon-induced IRF-7 gene expression due to inhibition of
ISGF3 formation by trichostatin A. J Virol. 77:7113–7119.
2003.PubMed/NCBI View Article : Google Scholar
|
|
32
|
de Lang A, Baas T, Smits SL, Katze MG,
Osterhaus AD and Haagmans BL: Unraveling the complexities of the
interferon response during SARS-CoV infection. Future Virol.
4:71–78. 2009.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Chan RW, Chan MC, Agnihothram S, Chan LL,
Kuok DI, Fong JH, Guan Y, Poon LL, Baric RS, Nicholls JM, et al:
Tropism of and innate immune responses to the novel human
betacoronavirus lineage C virus in human ex vivo respiratory organ
cultures. J Virol. 87:6604–6614. 2013.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Tang BS, Chan KH, Cheng VC, Woo PC, Lau
SK, Lam CC, Chan TL, Wu AK, Hung IF, Leung SY, et al: Comparative
host gene transcription by microarray analysis early after
infection of the Huh7 cell line by severe acute respiratory
syndrome coronavirus and human coronavirus 229E. J Virol.
79:6180–6193. 2005.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Au WC, Moore PA, Lowther W, Juang YT and
Pitha PM: Identification of a member of the interferon regulatory
factor family that binds to the interferon-stimulated response
element and activates expression of interferon-induced genes. Proc
Natl Acad Sci USA. 92:11657–11661. 1995.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Atwan Z, Wright J, Woodman A and Leppard
KN: Promyelocytic leukemia protein isoform II inhibits infection by
human adenovirus type 5 through effects on HSP70 and the interferon
response. J Gen Virol. 97:1955–1967. 2016.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Walker WE, Bozzi AT and Goldstein DR: IRF3
contributes to sepsis pathogenesis in the mouse cecal ligation and
puncture model. J Leukoc Biol. 92:1261–1268. 2012.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Spiegel M, Pichlmair A, Martínez-Sobrido
L, Cros J, García-Sastre A, Haller O and Weber F: Inhibition of
Beta interferon induction by severe acute respiratory syndrome
coronavirus suggests a two-step model for activation of interferon
regulatory factor 3. J Virol. 79:2079–2086. 2005.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Loukugamage KG, Hage A, de Vries M,
Valero-Jimenez AM, Schindewolf C, Dittmann M, Rajsbaum R and
Menachery VD: SARS-CoV-2 sensitive to type I interferon
pretreatment. bioRxiv: Apr 9, 2020 (Epub ahead of print). doi:
10.1101/2020.03.07.982264.
|
|
40
|
Zhao X, Guo F, Liu F, Cuconati A, Chang J,
Block TM and Guo JT: Interferon induction of IFITM proteins
promotes infection by human coronavirus OC43. Proc Natl Acad Sci
USA. 111:6756–6761. 2014.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Snijder EJ, van der Meer Y,
Zevenhoven-Dobbe J, Onderwater JJ, van der Meulen J, Koerten HK and
Mommaas AM: Ultrastructure and origin of membrane vesicles
associated with the severe acute respiratory syndrome coronavirus
replication complex. J Virol. 80:5927–5940. 2006.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Stertz S, Reichelt M, Spiegel M, Kuri T,
Martinez-Sobrido L, Garcia-Sastre A, Weber F and Koch G: The
intracellular sites of early replication and budding of
SARS-coronaviru. Virology. 361:304–315. 2007.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Cinatl J, Morgenstern B, Bauer G, Chandra
P, Rabenau H and Doerr HW: Treatment of SARS with human
interferons. Lancet. 362:293–294. 2003.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Mahlakõiv T, Ritz D, Mordstein M, DeDiego
ML, Enjuanes L, Müller MA, Drosten C and Staeheli P: Combined
action of type I and type III interferon restricts initial
replication of severe acute respiratory syndrome coronavirus in the
lung but fails to inhibit systemic virus spread. J Gen Virol.
93:2601–2605. 2012.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Channappanavar R, Fehr AR, Vijay R, Mack
M, Zhao J, Meyerholz DK and Perlman S: Dysregulated type I
interferon and inflammatory monocyte-macrophage responses cause
lethal pneumonia in SARS-CoV-infected mice. Cell Host Microbe.
19:181–193. 2016.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Zhou Q, Chen V, Shannon CP, Wei XS, Xiang
X, Wang X, Wang ZH, Tebbutt SJ, Kollmann TR and Fish EN:
Interferon-α2b Treatment for COVID-19. Front Immunol.
11(1061)2020.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Davoudi-Monfared E, Rahmani H, Khalili H,
Hajiabdolbaghi M, Salehi M, Abbasian L, Kazemzadeh H and
Yekaninejad MS: A randomized clinical trial of the efficacy and
safety of interferon beta-1a in treatment of severe COVID-19.
Antimicrob Agents Chemother. 64:e01061–e20. 2020.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Hung IF, Lung KC, Tso EY, Liu R, Chung TW,
Chu MY, Ng YY, Lo J, Chan J, Tam AR, et al: Triple combination of
interferon beta-1b, lopinavir-ritonavir, and ribavirin in the
treatment of patients admitted to hospital with COVID-19: an
open-label, randomised, phase 2 trial. Lancet. 395:1695–1704.
2020.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Hadjadj J, Yatim N, Barnabei L, Corneau A,
Boussier J, Smith N, Péré H, Charbit B, Bondet V, Chenevier-Gobeaux
C, et al: Impaired type I interferon activity and inflammatory
responses in severe COVID-19 patients. Science. 369:718–724.
2020.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Blanco-Melo D, Nilsson-Payant BE, Liu WC,
Uhl S, Hoagland D, Møller R, Jordan TX, Oishi K, Panis M, Sachs D,
et al: Imbalanced Host Response to SARS-CoV-2 Drives Development of
COVID-19. Cell. 181:1036–1045.e9. 2020.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Wilk AJ, Rustagi A, Zhao NQ, Roque J,
Martínez-Colón GJ, McKechnie JL, Ivison GT, Ranganath T, Vergara R,
Hollis T, et al: A single-cell atlas of the peripheral immune
response in patients with severe COVID-19. Nat Med. 26:1070–1076.
2020.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Lee JS and Shin EC: The type I interferon
response in COVID-19: Implications for treatment. Nat Rev Immunol.
20:585–586. 2020.PubMed/NCBI View Article : Google Scholar
|
